Companies › Pulmovant
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| inhaled mosliciguat soluble guanylate cyclase stimulator | GUCY1A1, GUCY1B1 | Phase 3 | Pulmonary Hypertension | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07333183 | inhaled mosliciguat | Phase 2 | Pulmonary Hypertension | Cardiovascular | Dec 2026 |
| NCT06635850 | inhaled mosliciguat | Phase 2 | Pulmonary Hypertension | Cardiovascular | Jan 2028 |
| NCT07816185 | inhaled mosliciguat | Phase 3 | Pulmonary Hypertension | Cardiovascular | Jan 2029 |
Merck & Co. (MSD) Kardigan Coherus Oncology Bayer Akebia Therapeutics
Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company EBI Anti Sepsis Agitated Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.